The acquired antibody programs, which are in the preclinical process, target platelet derived growth factor and angiopoietin2, respectively.
Regeneron will pay Sanofi $20 million upfront for the two programs and up to $45 million for sales royalties and development milestone payments.
More Articles on Ophthalmology:
Utah Valley Eye Center Joins Effort to Provide Car in Mali
Dr. Rona Silkiss to Perform Cosmetic Oculofacial Plastic Surgery at North Bay ASC
Palmetto Eye & Laser Center Offers Alcon WaveLight Procedures
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
